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Effect of chronic metabolic acidosis on the growth hormone/IGF-1
endocrine axis. The effects of metabolic acidosis on growth hormone and
IGF-1 are poorly understood. We investigated the effects of chronic
metabolic acidosis (induced by administration of NH4CI, 4.2 mmol/kg
body wt/day) on the growth hormone!IGF-1 endocrine axis in 6 normal
male volunteers during metabolic balance conditions. NH4CI administra-
tion resulted in hyperchloremic metabolic acidosis with plasma bicarbon-
ate decreasing from 25 0.4 to 15.5 0.9 mmol!liter (P < 0.001).
Metabolic acidosis significantly decreased serum IGF- 1 concentration
from 45 6 to 33 6 nmol/liter (P = 0.002), while serum IGF binding
protein 3 concentration was not affected significantly. The growth hor-
mone response to growth hormone releasing factor administration (1 jg
per kg body wt, intravenous bolos) was enhanced significantly during
acidosis. The IGF-1 response to growth hormone administration (0.1 U kg
body wt subcutaneously, every 12 hr for 48 hr) was blunted significantly
during acidosis. Apparent endogenous serum half-life and metabolic
clearance rates of growth hormone were not altered significantly by
acidosis. Metabolic acidosis in humans results in a significant decrease in
serum IGF-1 concentration without a demonstrable effect on IGF binding
protein 3, and is related to a resistance to the hepatocellular action of
growth hormone. The primary defect in the growth hormone/IGF-1 axis
occurs via an impaired IGF-1 response to circulating growth hormone with
consequent diminution of normal negative feedback inhibition of IGF-1
on growth hormone, as evidenced by the exaggerated growth hormone
response to growth hormone releasing factor administration.
Chronic metabolic acidosis results in sustained negative nitro-
gen balance in humans, which is independent of nutritional
deficiencies [1]. The mechanism(s) of acidosis-induced nitrogen
wasting is(are) poorly understood in humans. Improved under-
standing of these mechanisms is important since nitrogen wasting,
when prolonged, results in a progressive reduction in lean body
mass in a variety of disease states associated with metabolic
acidosis (such as end-stage renal disease, cancer and AIDS). This
may affect the prognosis of patients with metabolic acidosis
adversely since the magnitude of depletion of lean body mass is an
effective predictor of the interval to death in such conditions [2, 31.
Growth retardation associated with renal-tubular acidosis in
children is reversible upon alkali treatment [41. In rats, metabolic
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acidosis has been shown to decrease growth hormone (GH)
secretion and insulin-like growth factor (IGF)-1 levels with no
significant effects (vs. pair-fed rats) on hepatic IGF-1 and GH
receptor mRNA expression [5, 6]. Preliminary data from our
previous report suggested that the IGF-1 concentration was
reduced during sustained mineral acidosis in normal human
subjects [1]. The GH/IGF-1 endocrine axis provides for protein
anabolism and enhanced lean body mass, not only during linear
growth, but over the entire life span [7, 8]. Therefore, suppression
of GH/IGF-1 could mediate the effects of metabolic acidosis on
nitrogen balance and, ultimately, lean body mass.
Potassium depletion in rats resulted in reduced serum IGF-l
concentrations and a blunted GH response to growth hormone
releasing factor (GRF), suggesting that a hypothalamic/pituitary
defect is responsible, at least in part, for diminished serum
concentrations of GH and IGF-1 in that condition [9]. Calorie!
protein deprivation in humans results in large increments in the
24-hour integrated serum GH concentration and GH pulsatile
secretion frequency caused by augmented GRF release despite a
reduction in serum IGF-i concentration [10, 11]. Resistence of
IGF-1 production to hepatic GH action is present in both
prolonged fasting and protein deprivation, with the defect in
fasting attributable to a reduction in GH-receptor number and to
a post-receptor defect in protein restriction [12, 13]. Since pro-
longed fasting is accompanied by chronic metabolic acidosis and
potassium depletion, and since chronic metabolic acidosis is
commonly accompanied by potassium depletion (such as renal
tubular acidosis types 1 and 2, diarrhea, NH4C1 ingestion),
investigation of the effect of chronic metabolic acidosis on the
GH/IGF-1 axis in humans may be of substantial pathophysiolog-
ical and clinical importance.
Accordingly, the present studies were designed to evaluate the
GH/IGF-1 axis prior to and following the experimental induction
of chronic mineral acidosis in normal human subjects under
conditions of constant dietary intake.
Methods
The protocol was designed to measure the effects of chronic
NH4CI-induced metabolic acidosis on the growth hormone-IGF-1
endocrine axis in normal humans. Six normal male subjects were
examined during metabolic balance studies. None were smokers
nor were taking any drugs before and during the study. They
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Table 1. Effect of chronic NH4CI administration on fasting blood acid-base and plasma electrolyte composition
+H
nmol/liter
PaCO2
mm Hg
HCO3
Unmeasured
anions Na K C1 .Creatinine
clearance
mmoi/liter mi/sec
Control 38.2
0.7
41.0
0.9
25.1)
0.4
18.0
0.5
142
0.5
4.2
0.1
103
1
2.05
0.08
Acidosis 48.0
0.9
31.2°
1.4
15.5°
0.9
17.5
0.8
141
0.9
3.7°
0.1
113°
2
2.00
0.06
U <0.005
ingested a constant metabolic diet for > five days before the study
(prefeeding phase) and during the two study periods (control and
acidosis).
To characterize the acid-base and electrolyte status, 24 hour
urines were collected and fasting arterialized blood samples [14]
were obtained in a heparin-coated syringe from a heated hand or
forearm vein at 7 a.m. Blood samples were accepted if partial
pressure of oxygen was > 70 mm Hg (9.3 kPa). For hormonal
analysis, daily blood samples were obtained at 7 am. and samples
were kept on ice until centrifuged at 4°C. The serum samples were
stored at —30°C until analyzed. During this study the TSH
response to the intranasal administration of 2 mg TRH was
determined and reported elsewhere [15].
All subjects volunteered for the study, were paid for their
participation from institutional resources, and gave informed
consent. The study protocol was approved by the ethics committee
of the Kantonsspital St. Gallen, Switzerland.
Experimental design
After establishment of the metabolic steady state [daily varia-
tion of plasma bicarbonate concentration by no more than 1.5
mmol/liter and by < 3 mm Hg (0.4 kPa) for PaCO2J, the growth
hormone response to synthetic growth hormone releasing factor
(GRF 1-44; Sanofi Winthrop, 1 j.tg/kg body wt as an i.v. bolus) was
determined. Forty-five minutes after administration of GRF,
octreotide (Sandoz, Basle, Switzerland) was given (50 ig as an i.v.
bolus, followed by a constant infusion of 50 j.gIhr). During this
study the TSH response to the intranasal administration of 2 mg
of TRH was also determined [15]. The TRH test was performed
at least 48 hours before the GRF test. Two days after the GRF
test, the response of serum IGF-1 concentration to the subcuta-
neous administration of human recombinant growth hormone (0.1
U/kg body wi every 12 hr for 48 hr; Genotropin, Kabi Pharmacia,
Sweden) was determined.
The control period lasted until IGF-i serum concentrations for
at least two consecutive days were not different from the IGF-1
concentrations both before the GRF test and before growth
hormone administration, respectively. IGF-1 serum concentration
fell to basal levels in all subjects by 72 hours after the last dose of
growth hormone. After the control period, metabolic acidosis was
induced by oral administration of NH4CI (4.2 mmol/kg body
wt/day) in gelatin capsules in six divided doses. The GRF test was
repeated on day 5 of the acidosis period. The TRH test was
repeated on day 6 of the acidosis period [151. At the end of day
seven of acidosis, growth hormone administration was repeated
(0.1 U/kg body wt every 12 hr for 48 hr) and the IGF-1 response
determined. Observations of IGF-1 concentration were continued
Analytical procedures
Analysis of plasma and urine electrolyte and acid-base compo-
sition was performed as described previously [16]. IGF-1 was
determined radioimmunometrically after acid-ethanol extraction
of serum [17]. IGF-BP3 was determined radioimmunometrically
in serum using an antibody against pure acid-stabile 53 kDa
binding subunit extracted from serum Cohn fraction IV [181.
Growth hormone in serum was measured using an IRMA [19].
Calculations
Serum half-life (t 1/2) was calculated from the decay rate of
serum growth hormone concentration using a monoexponential
regression model [20]. In the control period, the t 1/2 was
calculated both for the decrease after achievement of peak GH
concentration (at least 3 consecutive GH concentrations were
decreasing) and for the GH concentrations following intravenous
administration of octreotide (Sandoz; 45 mm post-GRF, 50 .tg as
an i.v. bolus followed by an infusion of 50 pg/hr). In the acidosis
period, t 1/2 was calculated for the decrease following the time
points when GH concentration had reached the same level as in
the control period (peak concentration and after octreotide).
The metabolic clearance rate (MCR) for GH (mI/kg/mm) was
estimated using the monoexponential growth hormone t 1/2 and
assuming an average volume of distribution (DS) of 8.4%, accord-
ing to the following equations [21]:
MCR = (DS)(ln2/t 1/2)
DS = 0.084 x wt (kg)
Results are reported as means SEM unless stated otherwise.
Statistical significance was determined by Student's two-tailed
t-test for paired data.
pH
U
Net acid Na
rnmol/24 hr
K
mmo
CL
1/24 hr
Control 6.10 47.9 134 84 141
Acidosis 5.23"
+ 0.14
318.4°
19.2
138
8
87
7
457°
19
Table 2. Effect of chronic NH4CI administration on urinary acid-base
and electrolyte excretion
for 72 hours after the last dose of growth hormone administration, a P < 0.005
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Results
NH4CI administration resulted in sustained hyperchioremic
metabolic acidosis (Table 1). Plasma bicarbonate concentration
decreased significantly from 25.0 0.4 in the control period to
15.5 0.9 mmol/liter during acidosis (P < 0.001). Creatinine
clearance was not affected significantly by acidosis (2.05 0.08 vs.
2.00 0.06 mI/second, NS). NH4CI administration induced a
significant fall in plasma potassium concentration from 4.2 0.1
to 3.7 0.1 mmol/liter (P < 0.0025), consistent with our previous
observation of renal hypokalemia and negative sodium balance in
chronic metabolic acidosis [161. The effects of chronic NH4C1
administration on urine acid-base and electrolyte compostion are
shown in Table 2. All subjects tolerated NH4CI well and lost
weight (2.3 0.8 kg for the 7-day acidosis period before growth
hormone administration, P < 0.025) as reported previously [16].
As illustrated in Figure 1, serum IGF-1 concentration fell
significantly from 44.5 6.3 nmol/liter during control period to
33.4 6.0 nmol/liter (P = 0.002) after seven days of metabolic
acidosis. Figure 1 also illustrates that the serum concentration of
IGF binding protein 3 was not affected significantly by acidosis:
3.0 0.2 mg/liter during control and 3.0 0.3 mg/liter during
acidosis. The steady-state basal serum GH concentrations in-
creased slightly, hut insignificantly, from 0.15 0.05 to 0.35
0.05 ftg/liter at 0700 (am.) and from 0.10 0.02 to 0.40 0.05
jtg/liter at 1700 (p.m.) during chronic acidosis.
To further evaluate the level of inhibition of metabolic acidosis
on the GH/IGF-1 endocrine axis, the GH response to GRF
administration (1 pg/kg body wt as an i.v. bolus) was examined. As
illustrated in Figure 2, the GRF-stimulated OH response was
significantly greater during chronic metabolic acidosis as com-
pared to control. This exaggerated response is evidence for a loss
of normal feedback inhibition owing to reduced IGF-1 levels. The
results of this experiment are most easily explained by a primary
suppression of hepatic IGF-1 synthesis/secretion.
Based on the results of the GRF test and basal OH serum
concentrations, the integrated 24-hour secretion rate of GH
would be expected to be increased in response to acidosis. IGF-l
suppression might, therefore, be the result of hepatic OH insen-
sitivity. To examine this possibility, we evaluated the IOF-1
response to administration of high doses of OH (0.1 U/kg body wt
every 12 hr for 48 hr) during control and acidosis periods. Figure
3 illustrates that the IGF-l response to OH administration was
significantly blunted during the acidosis period. This effect could
he due to a OH receptor-mediated resistance to the hepatic action
of OH and/or an independent post-receptor suppressive effect of
metabolic acidosis on the hepatic synthesis of IGF-1. A potential
role for potassium depletion (Tables I and 2) in mediating the
present finding of a blunted IGF-1 response to OH administration
cannot be assessed at present since there are no reports of this
response under conditions of potassium depletion in any species.
The GRF test was also used to estimate the cndogenous
half-lives and metabolic clearance rates (MCR) of Gil before and
during secretory inhibition by octreotide. Since MCR decreases
and serum half-life increases with increasing serum concentra-
tions of OH [20], half-life and MCR during acidosis were esti-
mated from those portions of the decay curves corresponding to
identical serum Gil concentrations. The results of these determi-
nations, shown in Table 3, demonstrate that there were no
significant differences in the serum half-life and MCR between
control and acidosis periods. These results provide evidence that
the decreased serum IOF-1 levels in chronic metabolic acidosis
cannot he explained by decreased half-life or increased MCR of
serum Gil.
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Fig. 1. Effect of chronic metabolic acidosis
on serum JGF-1 (A) and IGF-BP3 (B)
concentrations in humans. Metabolic acidosis
was induced by administration of NH4CI (4.2
mmol/kg body wt/day).
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Fig. 2. Growth hormone response to growth hormone releasing Jctor (GRF,
1 pg/kg body wt, iv. bolus). Forty-five minutes after GRF, octreotide was
administered as indicated (time point: 60 mm).
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Control 36 10 15 5 21 5 10 3 77 9 161 34
Acidosis 45 12' 28 7 20 4 11 2 74 8 154 22
Serum half-time (t 1/2) and MCR were calculated for identical serum
concentrations during both study periods (that is, two GH serum concen-
trations measured during control period were chosen for comparison: GH
peak concentration after GRF administration and GH concentration at
the beginning of octreotide administration). Abbreviations are: Cp, the
peak GH concentration after GRF administration; Coct, GH concentra-
tion at the beginning of octreotide administration; MCRp,oct, metabolic
clearance rate after peak concentration and after concentration at the
beginning of octreotide administration, respectively.
a P < 0.05
Discussion
The present studies demonstrate that induction of chronic
metabolic acidosis in human subjects results in a significant
reduction of serum IGF-1 concentration in association with an
apparent insensitivity to the hepatocellular action of GH, as
evidenced by the blunted IGF-l response to administration of
pharmacological doses of GH. The acidosis-induced reduction of
serum TGF-1 concentration was associated with an accentuated
increase in serum GH concentration in response to GRF admin-
istration, as evidence for a sustained loss of normal feedback
inhibition of pituitary GH secretion owing to reduced circulating
levels of IGF-1.
A central novel finding of the present studies is that CMA
induces apparent insensitivity to GH in humans (Fig. 3). These
studies, however, were not designed to analyze the mechanism(s)
of this insensitivity and studies at the cellular level are needed to
determine whether alterations in OH receptor regulation, postre-
ceptor signal transduction defects and/or defects in IGF-1 synthe-
sis [22] are primarily responsible.
The pathophysiology of acidosis-induced decrements in serum
IGF-1 concentration appears similar to that reported during
Fig. 3. IGF-1 response to growth hormone
administration in metabolic acidosis. Symbols96 120 are: (. ...) control; ( ) acidosis. Growth
hormone was administered as indicated (0.1
U/kg body wt/dose). p < 0.05
prolonged fasting in normal subjects, where increased 24-hour
integrated serum GH concentration and GH pulsatile secretory
frequency have been reported [10, 11]. However, the GH secre-
tory response to GRF has not been reported during fasting.
Resistence of IGF-1 production to hepatic GH action occurs in
both prolonged fasting and in protein deprivation, with the defect
in fasting attributable to a reduction in GH receptor number [12]
and to a post-receptor defect in protein restriction [13]. Reduc-
tions in hepatic GH receptor mRNA and hepatic IGF-1 mRNA
expression have been reported for NH4CI-induced metabolic
acidosis in rats [6], although the reduction was not observed when
compared to pair-fed non-acidotic rats. The reduction in hepatic
IGF-1 mRNA has not been confirmed [23].
The frequency and magnitude of GH secretion in chronic
metabolic acidosis in adult humans has not been reported, but is
expected to be increased based on the present finding of a greatly
augmented GRF-induced GH response with its implications for
diminution of pituitary-level feedback inhibition. A brief period (3
hr) of NH4C1 loading has been reported to result in significant
elevation in plasma GH concentration in normal subjects [24].
The present finding of an elevated mean value, tendentiously
increased but statistically unchanged basal 7 a.m. and 5 p.m.
serum GH concentrations in acidotic subjects, is not inconsistent
with an augmented 24-hour integrated GH secretion rate inas-
much as OH secretion occurs in brief, episodic pulses throughout
the day.
The mechanism whereby decrements in serum IGF-1 concen-
tration in diverse conditions result in enhanced OH secretion has
been investigated both in vitro and in vivo with evidence provided
for IGF-1-induced negative feedback inhibition of OH secretion
at both pituitary and hypothalamus [10, 25, 26]. Importantly, it has
been demonstrated that fasting-induced augmented GH secretion
in normal subjects occurs under circumstances of diminished
negative feedback regulation owing to reduced IGF-1 levels [10].
Since chronic mineral acidosis and other causes of chronic
metabolic acidosis result in potassium depletion, the possibility
might be considered that the acidosis-induced abnormalities in
the OH/IGF-1 axis are secondary to disordered potassium metab-
olism. This possibility is unlikely based on the observation that the
.1. . .
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Table 3. Effect of metabolic acidosis on serum half-time (t 1/2) and
metabolic clearance rate (MCR) of GH
Cp Coct t l/2p t l/2oct MCRp MCRoct
gg/liter mm mi/mm/rn2
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serum IGF-1 levels are reduced significantly in potassium de-
pleted rats in association with a diminished rather than acidosis-
induced augmented GH response to GRF administration [9].
In contrast to the findings in protein deprivation [27], IGFBP-3
concentrations were unchanged during metabolic acidosis when
total serum IGF-1 concentrations were reduced. Thus, in meta-
bolic acidosis free IGF-1 levels are likely to be reduced.
Chronic metabolic acidosis results in primary hypothyroidism in
humans (unpublished observations) [15]. Since hypothyroidism
results in decreased GH secretion in rats and in decreased plasma
IGF-1 concentrations in humans [28] and rats [291, it might be
predicted that the acidosis-induced alterations in the GH/IGF-1
axis are mediated, at least in part, by concurrent hypothyroidism.
This is unlikely for several reasons: In both hypothyroid rats [30,
31] and humans [32], the serum GH response to GRF adminis-
tration is blunted, not enhanced as shown in the present study.
Moreover, the serum IGF-1 response to GH administration in
human hypothyroidism is reported to be unimpaired [33] rather
than the blunted IGF-1 response demonstrated in the acidotic
subjects of the present studies. Human hypothyroidism has also
been reported to result in impaired bloactivity of circulating
IGF-1 as assessed with an IGF-1 cartilage sulfation bioassay [28],
but it remains to be investigated whether acidosis results in
impaired IGF-1 bioactivity.
In summary and conclusion, the central findings of the present
studies show that metabolic acidosis in humans results in a
significant decrease in serum IGF-1 concentration that is inde-
pendent of a change in IGFBP-3 concentration and related to a
demonstrable insensitivity to the hepatocellular action of GH.
The primary hepatocellular defect within the GH/IGF-1 axis
results in diminished negative feedback inhibition of IGF-1 on
GH as evidenced by the enhanced serum GH response to GRF
administration. The present finding of an unchanged MCR for
GH in chronic metabolic acidosis will enhance interpretation of
future studies in which pulsatile serum GH concentration profile
is determined in this disorder. The unchanged metabolic clear-
ance rate will permit determination of alterations in GH secretion
rate from serum OH concentrations in acidotic subjects.
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